Fierce Pharma

SEPTEMBER 8, 2024

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.

354

354

MedCity News

SEPTEMBER 8, 2024

As poverty, food insecurity, inadequate housing, and complex comorbidities persist, it is essential that rural healthcare leaders have tools and systems in place to address the health of their neighbors. The post Rural Healthcare Goes Beyond Care: Targeting SDOH to Improve Health Outcomes appeared first on MedCity News.

Healthcare 133

Healthcare Healthcare Food Transportation 133

pharmaphorum

SEPTEMBER 8, 2024

CDC reports the first-ever US case of an H5 strain of avian influenza without a known occupational exposure to sick or infected animals

119

119

MedCity News

SEPTEMBER 8, 2024

As the FDA continues its work to ensure that AI is deployed safely within healthcare, there are a couple prevalent issues that frequently pop up, said Luke Ralston, one of the agency’s reviewers. The post These Are 2 of The Biggest Issues with Healthcare AI, According to an FDA Reviewer appeared first on MedCity News.

Healthcare 129

Healthcare Healthcare FDA 129

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

pharmaphorum

SEPTEMBER 8, 2024

Results of Ideate-Lung01 trial at WCLC back up MSD and Daiichi Sankyo's decision to move anti-B7-H3 ADC I-Dxd into phase 3 for small cell lung cancer

111

111

MedCity News

SEPTEMBER 8, 2024

NeOnc Technologies is preparing to go public via the less common path of a direct listing as it continues mid-stage testing of its intranasally administered brain cancer drug. Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week. The post A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets appeared first on MedCity News.

Marketing 119

Marketing Biopharma Pharma 119

MedCity News

SEPTEMBER 8, 2024

The ruling, which limits federal agencies’ power to interpret ambiguous laws, now leaves crucial legislation like the Mental Health Parity and Addiction Equity Act vulnerable to court challenges, potentially unraveling years of hard-won progress. The post Supreme Court’s Chevron Decision Threatens Decades of Progress in Access to Mental Health Care appeared first on MedCity News.

114

114

Clarivate

SEPTEMBER 8, 2024

A new Clarivate report [1] explores Standard Essential Patents Landscape of 5G RedCap The RedCap (Reduced Capability) feature was introduced by 3GPP in Release-17 to cater to the growing demand for 5G New Radio (NR) devices with reduced complexity. 5G RedCap, also known as NR-Light, addresses the need for simpler, energy efficient and cost effective 5G NR devices.

Distribution 52

Distribution Leads 52

PharmaTech

SEPTEMBER 8, 2024

Drug stability impacts efficacy and safety. Choosing the right packaging is crucial. This paper outlines key factors affecting stability and provides packaging guidelines.

Safety 52

Safety 52

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma.

52

52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

PharmaTech

SEPTEMBER 8, 2024

Insights into molecular behaviors and predictive capabilities are bringing numerous benefits.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Pearson Syndrome.

52

52

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Technology

SEPTEMBER 8, 2024

MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Subacute Necrotizing Encephalomyelopathy (Leigh Disease).

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

Pharmaceutical Technology

SEPTEMBER 8, 2024

Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer.

Pharma 52

Pharma 52

Pharmaceutical Technology

SEPTEMBER 8, 2024

Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Technology

SEPTEMBER 8, 2024

Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).

Engineering 40

Engineering 40

Pharmaceutical Technology

SEPTEMBER 8, 2024

RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

MAR-001 is under clinical development by Marea Therapeutics and currently in Phase II for Hypertriglyceridemia.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Autoimmune Disorders.

40

40

Advertisement

Distribution

Pharmaceutical Technology

SEPTEMBER 8, 2024

JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Inflammation.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

Chenodiol is under clinical development by Mirum Pharmaceuticals and currently in Pre-Registration for Cerebrotendinous Xanthomatosis.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

SEPTEMBER 8, 2024

FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer.

Leads 40

Leads Pharmaceutical 40

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales